Scipharm SARL

Luxembourg

Back to Profile

1-29 of 29 for Scipharm SARL Sort by
Query
Aggregations
IP Type
        Patent 23
        Trademark 6
Jurisdiction
        World 12
        United States 8
        Canada 6
        Europe 3
Date
2023 1
2021 7
Before 2020 21
IPC Class
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin 6
A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells 6
A61K 9/00 - Medicinal preparations characterised by special physical form 5
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 4
C07C 47/565 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring 4
See more
NICE Class
09 - Scientific and electric apparatus and instruments 6
10 - Medical apparatus and instruments 6
42 - Scientific, technological and industrial services, research and design 6
Status
Pending 1
Registered / In Force 28

1.

COMPLEX OF 7-DEACETYLFORSKOLIN AND PVP

      
Application Number 17794946
Status Pending
Filing Date 2021-01-22
First Publication Date 2023-11-02
Owner SciPharm S.à.r.l (Luxembourg)
Inventor Kubin, Andreas

Abstract

An object of the invention is a complex of 7-deacetyl-forskolin (7-DAFSK) and polyvinylpyrrolidone (PVP). Furthermore, the invention relates to a process for preparing such a 7-DAFSK-PVP complex and to a pharmaceutical composition containing such a complex.

IPC Classes  ?

  • A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin

2.

SCI MEDES

      
Application Number 1628197
Status Registered
Filing Date 2021-10-13
Registration Date 2021-10-13
Owner SciPharm S.à.r.l (Luxembourg)
NICE Classes  ?
  • 09 - Scientific and electric apparatus and instruments
  • 10 - Medical apparatus and instruments
  • 42 - Scientific, technological and industrial services, research and design

Goods & Services

Application software for connecting medical devices to data processing systems and/or clouds. Medical devices; implantable/ambulatory infusion pumps. Scientific and technological services and research for development and distribution of implantable/ambulatory infusion pumps; design, development and implementation of operating software for accessing and using a computing network to connect medical devices to data processing systems and/or clouds; remote monitoring and distant programming services for medical devices; software as a service to connect medical devices; platform as a service to connect medical devices.

3.

SCIMEDES

      
Application Number 1628906
Status Registered
Filing Date 2021-10-13
Registration Date 2021-10-13
Owner SciPharm S.à.r.l (Luxembourg)
NICE Classes  ?
  • 09 - Scientific and electric apparatus and instruments
  • 10 - Medical apparatus and instruments
  • 42 - Scientific, technological and industrial services, research and design

Goods & Services

Application software for connecting medical devices to data processing systems and/or clouds. Medical devices; implantable/ambulatory infusion pumps. Scientific and technological services and research for development and distribution of implantable/ambulatory infusion pumps; design, development and implementation of operating software for accessing and using a computing network to connect medical devices to data processing systems and/or clouds; remote monitoring and distant programming services for medical devices; software as a service to connect medical devices; platform as a service to connect medical devices.

4.

Miscellaneous Design

      
Application Number 1627959
Status Registered
Filing Date 2021-10-13
Registration Date 2021-10-13
Owner SciPharm S.à.r.l (Luxembourg)
NICE Classes  ?
  • 09 - Scientific and electric apparatus and instruments
  • 10 - Medical apparatus and instruments
  • 42 - Scientific, technological and industrial services, research and design

Goods & Services

Application software for connecting medical devices to data processing systems and/or clouds. Medical devices; implantable/ambulatory infusion pumps. Scientific and technological services and research for development and distribution of implantable/ambulatory infusion pumps; design, development and implementation of operating software for accessing and using a computing network to connect medical devices to data processing systems and/or clouds; remote monitoring and distant programming services for medical devices; software as a service to connect medical devices; platform as a service to connect medical devices.

5.

Process for preparing water soluble forskolin

      
Application Number 16476337
Grant Number 11234957
Status In Force
Filing Date 2018-01-09
First Publication Date 2021-05-20
Grant Date 2022-02-01
Owner SciPharm S.à.r.l (Luxembourg)
Inventor Kubin, Andreas

Abstract

The invention relates to a new method for preparing a complex of forskolin and cyclodextrin and inclusion complexes of forskolin and γ-cyclodextrins having a weight ratio of 1:0.2 to 1:4 (w/w). Pharmaceutical compositions comprising said complex and their use are also provided.

IPC Classes  ?

  • A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
  • A61K 47/40 - Cyclodextrins; Derivatives thereof
  • A61K 9/08 - Solutions

6.

SCIMEDES

      
Application Number 018453038
Status Registered
Filing Date 2021-04-15
Registration Date 2021-08-26
Owner SciPharm S.à.r.l (Luxembourg)
NICE Classes  ?
  • 09 - Scientific and electric apparatus and instruments
  • 10 - Medical apparatus and instruments
  • 42 - Scientific, technological and industrial services, research and design

Goods & Services

Application software for connecting medical devices to data processing systems and/or clouds. Medical devices; Implantable/ambulatory infusion pumps. Scientific and technological services and research for development and distribution of implantable/ambulatory infusion pumps; Design, development and implementation of operating software for accessing and using a computing network to connect medical devices to data processing systems and/or clouds; Remote monitoring and distant programming services for medical devices; Software as a service to connect medical devices; Platform as a service to connect medical devices.

7.

SCIMEDES

      
Application Number 018453345
Status Registered
Filing Date 2021-04-15
Registration Date 2021-08-26
Owner SciPharm S.à.r.l (Luxembourg)
NICE Classes  ?
  • 09 - Scientific and electric apparatus and instruments
  • 10 - Medical apparatus and instruments
  • 42 - Scientific, technological and industrial services, research and design

Goods & Services

Application software for connecting medical devices to data processing systems and/or clouds. Medical devices; Implantable/ambulatory infusion pumps. Scientific and technological services and research for development and distribution of implantable/ambulatory infusion pumps; Design, development and implementation of operating software for accessing and using a computing network to connect medical devices to data processing systems and/or clouds; Remote monitoring and distant programming services for medical devices; Software as a service to connect medical devices; Platform as a service to connect medical devices.

8.

Miscellaneous Design

      
Application Number 018453348
Status Registered
Filing Date 2021-04-15
Registration Date 2021-08-26
Owner SciPharm S.à.r.l (Luxembourg)
NICE Classes  ?
  • 09 - Scientific and electric apparatus and instruments
  • 10 - Medical apparatus and instruments
  • 42 - Scientific, technological and industrial services, research and design

Goods & Services

Application software for connecting medical devices to data processing systems and/or clouds. Medical devices; Implantable/ambulatory infusion pumps. Scientific and technological services and research for development and distribution of implantable/ambulatory infusion pumps; Design, development and implementation of operating software for accessing and using a computing network to connect medical devices to data processing systems and/or clouds; Remote monitoring and distant programming services for medical devices; Software as a service to connect medical devices; Platform as a service to connect medical devices.

9.

NOVEL PROCESS FOR PREPARING WATER SOLUBLE FORSKOLIN

      
Application Number EP2018050447
Publication Number 2018/127600
Status In Force
Filing Date 2018-01-09
Publication Date 2018-07-12
Owner SCIPHARM SÀRL (Luxembourg)
Inventor Kubin, Andreas

Abstract

The invention relates to a new method for preparing a complex of forskolin and cyclodextrin and inclusion complexes of forskolin and Ɣ-cyclodextrins having a weight ratio of 1:0.2 to 1:4 (w/w). Pharmaceutical compositions comprising said complex and their use are also provided.

IPC Classes  ?

10.

Composition for use in increasing engraftment efficacy of haematopoetic stem cells after transplantation

      
Application Number 15547059
Grant Number 10226465
Status In Force
Filing Date 2016-01-27
First Publication Date 2018-01-11
Grant Date 2019-03-12
Owner SCIPHARM SÀRL (Luxembourg)
Inventor
  • Freissmuth, Michael
  • Zebedin-Brandl, Eva-Maria
  • Kazemi, Zahra

Abstract

The present invention provides the new use of composition comprising at least one inhibitor of dipeptidyl peptidase IV (DPP-IV) for increasing migration and homing of haematopoetic progenitor cells in stem cell transplanted recipients, wherein said haematopoetic stem and/or progenitor cells had been treated in vitro with an engraftment enhancing compound, specifically with a prostacyclin analog and a cAMP enhancer before transplantation.

IPC Classes  ?

  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 35/12 - Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
  • A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
  • C12N 5/0789 - Stem cells; Multipotent progenitor cells

11.

COMPOSITION FOR USE IN INCREASING ENGRAFTMENT EFFICACY OF HAEMATOPOETIC STEM CELLS AFTER TRANSPLANTATION

      
Document Number 02973146
Status In Force
Filing Date 2016-01-27
Open to Public Date 2016-08-04
Grant Date 2024-01-09
Owner SCIPHARM SARL (Luxembourg)
Inventor
  • Freissmuth, Michael
  • Zebedin-Brandl, Eva-Maria
  • Kazemi, Zahra

Abstract

The present invention provides the new use of composition comprising at least one inhibitor of dipeptidyl peptidase IV (DPP-IV) for increasing migration and homing of haematopoetic progenitor cells in stem cell transplanted recipients, wherein said haematopoetic stem and/or progenitor cells had been treated in vitro with an engraftment enhancing compound, specifically with a prostacyclin analogue and a cAMP enhancer before transplantation.

IPC Classes  ?

  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
  • A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
  • A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61P 35/02 - Antineoplastic agents specific for leukemia

12.

COMPOSITION FOR USE IN INCREASING ENGRAFTMENT EFFICACY OF HAEMATOPOETIC STEM CELLS AFTER TRANSPLANTATION

      
Application Number EP2016051672
Publication Number 2016/120310
Status In Force
Filing Date 2016-01-27
Publication Date 2016-08-04
Owner SCIPHARM SÀRL (Luxembourg)
Inventor
  • Freissmuth, Michael
  • Zebedin-Brandl, Eva-Maria
  • Kazemi, Zahra

Abstract

The present invention provides the new use of composition comprising at least one inhibitor of dipeptidyl peptidase IV (DPP-IV) for increasing migration and homing of haematopoetic progenitor cells in stem cell transplanted recipients, wherein said haematopoetic stem and/or progenitor cells had been treated in vitro with an engraftment enhancing compound, specifically with a prostacyclin analogue and a cAMP enhancer before transplantation.

IPC Classes  ?

  • A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
  • A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
  • A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
  • A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
  • A61P 35/02 - Antineoplastic agents specific for leukemia

13.

COMPOSITION FOR THE TREATMENT OF HEPATIC VENO-OCCLUSIVE DISEASE

      
Application Number EP2016051675
Publication Number 2016/120311
Status In Force
Filing Date 2016-01-27
Publication Date 2016-08-04
Owner SCIPHARM SÀRL (Luxembourg)
Inventor
  • Freissmuth, Michael
  • Zebedin-Brandl, Eva-Maria
  • Kazemi, Zahra
  • Österreicher, Christoph
  • Lemberger, Ursula
  • Themanns, Madeleine

Abstract

The present invention provides a composition comprising a prostacyclin analogue, derivative or a pharmaceutically acceptable salt thereof, for use in preventing or treating the sinusoidal obstruction syndrome and/or hepatic veno-occlusive disease (VOD) as well as treatment regimens therefor.

IPC Classes  ?

  • A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
  • A61K 31/00 - Medicinal preparations containing organic active ingredients
  • A61K 31/5578 - Eicosanoids, e.g. leukotrienes having a pentalene ring system, e.g. carbacyclin, iloprost
  • A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
  • A61K 9/00 - Medicinal preparations characterised by special physical form

14.

Composition for the treatment of cystic fibrosis

      
Application Number 14978914
Grant Number 10086001
Status In Force
Filing Date 2015-12-22
First Publication Date 2016-06-23
Grant Date 2018-10-02
Owner SciPharm SaRL (Luxembourg)
Inventor
  • Freissmuth, Michael
  • Koenig, Xaver
  • Just, Christina

Abstract

The present invention provides compositions comprising a prostacyclin or prostacyclin analog, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analog for treating or preventing a condition associated with cystic fibrosis in a subject.

IPC Classes  ?

  • A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 31/5578 - Eicosanoids, e.g. leukotrienes having a pentalene ring system, e.g. carbacyclin, iloprost
  • A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin

15.

Active emergency supply valve

      
Application Number 14890862
Grant Number 10010672
Status In Force
Filing Date 2014-05-16
First Publication Date 2016-05-12
Grant Date 2018-07-03
Owner SciPharm SàRL (Luxembourg)
Inventor Fischer, Georg

Abstract

The present invention provides an emergency supply valve to support the in situ administration of a drug to a subject in need thereof, comprising an infusion needle connected to a movable piston, wherein said piston is forwarded by infusion solution unable to pass the regular drug line due to kinking or obstruction thereof, a self-sealing membrane that is disrupted by the infusion needle when the piston is in a forward position, a connecting unit that connects the needle to the regular drug conduit when the needle is in a forward position, and a pressure sensitive mechanism that retracts the piston from the forward position when an increased pressure of the drug supply is normalized and its use for the treatment of subjects in need thereof.

IPC Classes  ?

  • A61M 5/145 - Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. by means of pistons
  • A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
  • A61M 5/142 - Pressure infusion, e.g. using pumps
  • A61M 39/22 - Valves or arrangement of valves
  • A61M 39/24 - Check- or non-return valves

16.

Process for the preparation of treprostinil and derivatives thereof

      
Application Number 14401826
Grant Number 09346738
Status In Force
Filing Date 2013-05-22
First Publication Date 2015-05-07
Grant Date 2016-05-24
Owner SciPharm SaRL (Luxembourg)
Inventor
  • Jain, Nareshkumar
  • Kirkup, Michael
  • Marella, Michael
  • Ghone, Sanjeevani

Abstract

A method for the preparation of treprostinil and its derivatives is described. In contrast to prior art, this method utilizes an easily scalable enzymatic resolution of a key intermediate for making these compounds. Another significant improvement of the described method over prior methods is the regioselective Claisen rearrangement of a 5-allyloxy-benzaldehyde precursor, which is facilitated by a bromo substituent in 2-position.

IPC Classes  ?

  • C07C 59/115 - Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing halogen
  • C07C 51/377 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by hydrogenolysis of functional groups
  • C07C 47/565 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
  • C07C 47/575 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing ether groups, groups, groups, or groups
  • C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
  • C07C 59/72 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
  • C12P 31/00 - Preparation of compounds containing a five-membered ring having two side-chains in ortho position to each other, and having at least one oxygen atom directly bound to the ring in ortho position to one of the side-chains, one side-chain containing, no
  • C12P 41/00 - Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture

17.

NOVEL ACTIVE EMERGENCY SUPPLY VALVE

      
Application Number EP2014060117
Publication Number 2014/184358
Status In Force
Filing Date 2014-05-16
Publication Date 2014-11-20
Owner SCIPHARM SÀRL (Luxembourg)
Inventor Fischer, Georg

Abstract

The present invention provides an emergency supply valve to support the in situ administration of a drug to a subject in need thereof, comprising an infusion needle connected to a movable piston, wherein said piston is forwarded by infusion solution unable to pass the regular drug line due to kinking or obstruction thereof, a self-sealing membrane that is disrupted by the infusion needle when the piston is in a forward position, a connecting unit that connects the needle to the regular drug conduit when the needle is in a forward position, and a pressure sensitive mechanism that retracts the piston from the forward position when an increased pressure of the drug supply is normalized and its use for the treatment of subjects in need thereof.

IPC Classes  ?

  • A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
  • A61M 5/142 - Pressure infusion, e.g. using pumps
  • A61M 39/22 - Valves or arrangement of valves
  • A61M 39/24 - Check- or non-return valves

18.

PRESSURE ACTIVATED EMERGENCY SUPPLY VALVE

      
Document Number 02910127
Status In Force
Filing Date 2014-05-16
Open to Public Date 2014-11-20
Grant Date 2021-03-30
Owner SCIPHARM SARL (Luxembourg)
Inventor Fischer, Georg

Abstract

The present invention provides an emergency supply valve to support the in situ administration of a drug to a subject in need thereof, comprising an infusion needle connected to a movable piston, wherein said piston is forwarded by infusion solution unable to pass the regular drug line due to kinking or obstruction thereof, a self-sealing membrane that is disrupted by the infusion needle when the piston is in a forward position, a connecting unit that connects the needle to the regular drug conduit when the needle is in a forward position, and a pressure sensitive mechanism that retracts the piston from the forward position when an increased pressure of the drug supply is normalized and its use for the treatment of subjects in need thereof.

IPC Classes  ?

  • A61M 5/168 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters
  • A61M 5/142 - Pressure infusion, e.g. using pumps
  • A61M 39/22 - Valves or arrangement of valves
  • A61M 39/24 - Check- or non-return valves

19.

Composition for the treatment of cystic fibrosis

      
Application Number 13982399
Grant Number 09504663
Status In Force
Filing Date 2012-02-03
First Publication Date 2014-01-16
Grant Date 2016-11-29
Owner SciPharm SaRL (Luxembourg)
Inventor
  • Freissmuth, Michael
  • Gloeckel, Christina
  • Koenig, Xaver
  • Keuerleber, Simon

Abstract

The present invention provides a composition comprising at least one prostacyclin or prostacyclin analog or a pharmaceutically acceptable salt thereof and at least one phosphodiesterase (PDE) 4 inhibitor and optionally a further PDE inhibitor for use in preventing or treating cystic fibrosis by selectively increasing the cAMP levels in bronchoepithelial cells.

IPC Classes  ?

  • A61K 38/00 - Medicinal preparations containing peptides
  • C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
  • A01N 37/10 - Aromatic or araliphatic carboxylic acids, or thio-analogues thereof; Derivatives thereof
  • A61K 31/19 - Carboxylic acids, e.g. valproic acid
  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/44 - Non-condensed pyridines; Hydrogenated derivatives thereof
  • A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
  • A61K 31/5578 - Eicosanoids, e.g. leukotrienes having a pentalene ring system, e.g. carbacyclin, iloprost
  • A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

20.

Method for enhancing engraftment of haematopoetic stem cells

      
Application Number 13979332
Grant Number 10213464
Status In Force
Filing Date 2012-01-13
First Publication Date 2013-12-26
Grant Date 2019-02-26
Owner SCIPHARM SARL (Luxembourg)
Inventor
  • Freissmuth, Michael
  • Zebedin-Brandl, Eva-Maria
  • Bergmayr, Christian
  • Hussain, Filza

Abstract

The present invention provides a novel method for enhancing engraftment of haematopoetic stem cells by an ex-vivo pretreatment comprising the steps of obtaining a sample containing haematopoetic stem cells and admixing a prostacyclin analog to obtain a mixture, incubating said mixture for a period of time sufficient to stimulate G alphas-signalling in said cells and optionally and isolating said stimulated cells. Further, a composition comprising a prostacyclin analog for use in the treatment of individuals undergoing haematopoetic stem cell transplantation is provided.

IPC Classes  ?

  • A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
  • C12N 5/0789 - Stem cells; Multipotent progenitor cells

21.

IMPROVED PROCESS FOR THE PREPARATION OF TREPROSTINIL AND DERIVATIVES THEREOF

      
Document Number 02873280
Status In Force
Filing Date 2013-05-22
Open to Public Date 2013-11-28
Grant Date 2021-07-13
Owner SCIPHARM SARL (Luxembourg)
Inventor
  • Jain, Nareshkumar F.
  • Kirkup, Michael P.
  • Marella, Michael A.
  • Ghone, Sanjeevani A.

Abstract

Abstract Methods to produce treprostinal and intermediate compounds made in the process are disclosed. The intermediate compounds comprise a compound of formula I or formula II, o-PG2 0 X Ra a X R ¨0 Y.-- OPG1 OPG1 11 wherein, X is Br and Y is H; PG1 is selected from the group consisting of methyl, methoxymethyl, benzyloxymethyl, methoxyethoxymethyl, benzyl, 4-methoxybenzyl, 2,6-dichlorobenzyl, 3,4-dichloro- benzyl; -CH2COOH, -CH2COORx, and -CH2CH2OPG2; PG2 is is tetrahydropyranyl (THP), SiRiR2R3; CH20Rx, or tert- butyldimethylsilyl (TBDMS); R1, R2, and R3 are independently from one another selected from the group consisting of methyl, isopropyl, t-butyl, and phenyl; Ra is hydrogen, hydroxy -000ORx, -0S02Rx, CI, Br F, I, -SR, or -SO2Rx; and Rx is C1_4alkyl or aryl. Date Recue/Date Received 2020-04-28

IPC Classes  ?

  • C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
  • C07C 47/565 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
  • C07C 47/575 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing ether groups, groups, groups, or groups
  • C07C 51/08 - Preparation of carboxylic acids or their salts, halides, or anhydrides from nitriles
  • C12P 41/00 - Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture

22.

DERIVATIVES OF 6-BROMO-3-ALLYLOXYBENZALDEHYDE

      
Document Number 03118552
Status In Force
Filing Date 2013-05-22
Open to Public Date 2013-11-28
Grant Date 2023-10-31
Owner SCIPHARM SARL (Luxembourg)
Inventor
  • Jain, Nareshkumar F.
  • Kirkup, Michael P.
  • Marella, Michael, A.
  • Ghone, Sanjeevani A.

Abstract

The invention relates to compounds 4a and 5, useful to prepare Treprostinil, and methods of their synthesis. (see compound 4a and 5)

IPC Classes  ?

  • C07C 47/575 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing ether groups, groups, groups, or groups
  • C07C 45/61 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of C=O groups
  • C07C 47/565 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring

23.

PROCESS FOR THE PREPARATION OF TREPROSTINIL AND DERIVATIVES THEREOF

      
Application Number EP2013060472
Publication Number 2013/174848
Status In Force
Filing Date 2013-05-22
Publication Date 2013-11-28
Owner SCIPHARM SÀRL (Luxembourg)
Inventor
  • Jain, Nareshkumar F.
  • Kirkup, Michael P.
  • Marella, Michael A.
  • Ghone, Sanjeevani, A.

Abstract

A method for the preparation of treprostinil and its derivatives is described. In contrast to prior art, this method utilizes an easily scalable enzymatic resolution of a key intermediate for making these compounds. Another significant improvement of the described method over prior methods is the regioselective Claisen rearrangement of a 5-allyloxy-benzaldehyde precursor, which is facilitated by a bromo substituent in 2-position.

IPC Classes  ?

  • C07C 67/29 - Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by introduction of oxygen-containing functional groups
  • C07C 69/18 - Acetic acid esters of trihydroxylic compounds
  • C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
  • C12P 41/00 - Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
  • C07C 47/565 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing hydroxy groups all hydroxy groups bound to the ring
  • C07C 47/575 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing ether groups, groups, groups, or groups
  • C07C 51/377 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by hydrogenolysis of functional groups
  • C07C 59/72 - Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings

24.

NOVEL COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS

      
Document Number 02826183
Status In Force
Filing Date 2012-02-03
Open to Public Date 2012-08-16
Grant Date 2019-05-14
Owner SCIPHARM SARL (Luxembourg)
Inventor
  • Freissmuth, Michael
  • Gloeckel, Christina
  • Koenig, Xaver
  • Keuerleber, Simon

Abstract

The present invention provides a composition comprising at least one prostacyclin or prostacyclin analogue or a pharmaceutically acceptable salt thereof and at least one phosphodiesterase (PDE) 4inhibitor and optionally a further PDE inhibitor for use in preventing or treating cystic fibrosis by selectively increasing the cAMP levels in bronchoepithelial cells.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/28 - Dragees; Coated pills or tablets
  • A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
  • A61K 31/37 - Coumarins, e.g. psoralen
  • A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
  • A61K 31/404 - Indoles, e.g. pindolol
  • A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
  • A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/44 - Non-condensed pyridines; Hydrogenated derivatives thereof
  • A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
  • A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
  • A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine

25.

NOVEL COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS

      
Application Number EP2012051881
Publication Number 2012/107364
Status In Force
Filing Date 2012-02-03
Publication Date 2012-08-16
Owner SciPharm SàRL (Luxembourg)
Inventor Freissmuth, Michael

Abstract

The present invention provides a composition comprising at least one prostacyclin orprostacyclin analogue or a pharmaceutically acceptable salt thereof and at least one compound selected from the group consisting of leukotriene antagonists, prostaglandin antagonists and duramycin or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides a composition comprising Treprostiniland a compound from the group consisting of leukotriene antagonists, prostaglandin antagonists and duramycinor a pharmaceutically acceptable salt thereof.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/28 - Dragees; Coated pills or tablets
  • A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
  • A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
  • A61K 31/404 - Indoles, e.g. pindolol
  • A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
  • A61K 31/47 - Quinolines; Isoquinolines
  • A61K 38/00 - Medicinal preparations containing peptides
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61P 43/00 - Drugs for specific purposes, not provided for in groups

26.

NOVEL COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS

      
Application Number EP2012051880
Publication Number 2012/107363
Status In Force
Filing Date 2012-02-03
Publication Date 2012-08-16
Owner SCIPHARM SÀRL (Luxembourg)
Inventor
  • Freissmuth, Michael
  • Gloeckel, Christina
  • Koenig, Xaver
  • Keuerleber, Simon

Abstract

The present invention provides a composition comprising at least one prostacyclin or prostacyclin analogue or a pharmaceutically acceptable salt thereof and at least one phosphodiesterase (PDE) 4inhibitor and optionally a further PDE inhibitor for use in preventing or treating cystic fibrosis by selectively increasing the cAMP levels in bronchoepithelial cells.

IPC Classes  ?

  • A61K 9/00 - Medicinal preparations characterised by special physical form
  • A61K 9/28 - Dragees; Coated pills or tablets
  • A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
  • A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
  • A61K 31/37 - Coumarins, e.g. psoralen
  • A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
  • A61K 31/404 - Indoles, e.g. pindolol
  • A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
  • A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
  • A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
  • A61K 31/44 - Non-condensed pyridines; Hydrogenated derivatives thereof
  • A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
  • A61K 31/472 - Non-condensed isoquinolines, e.g. papaverine
  • A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine

27.

PROSTACYCLIN ANALOGUE COMPOSITION AND METHOD FOR ENHANCING ENGRAFTMENT OF HAEMATOPOETIC STEM CELLS

      
Document Number 02824113
Status In Force
Filing Date 2012-01-13
Open to Public Date 2012-07-19
Grant Date 2020-04-14
Owner SCIPHARM SARL (Luxembourg)
Inventor
  • Freissmuth, Michael
  • Zebedin-Brandl, Eva-Maria
  • Bergmayr, Christian
  • Hussain, Filza

Abstract

The present invention provides a novel method for enhancing engraftment of haematopoetic stem cells by an ex-vivo pretreatment comprising the steps of obtaining a sample containing haematopoetic stem cells and admixing a prostacyclin analogue to obtain a mixture, incubating said mixture for a period of time sufficient to stimulate G alphas-signalling in said cells and optionally and isolating said stimulated cells. Further, a composition comprising a prostacyclin analogue for use in the treatment of individuals undergoing haematopoetic stem cell transplantation is provided.

IPC Classes  ?

  • A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
  • C12N 5/0789 - Stem cells; Multipotent progenitor cells
  • A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells

28.

METHOD FOR ENHANCING ENGRAFTMENT OF HAEMATOPOETIC STEM CELLS

      
Application Number EP2012050484
Publication Number 2012/095511
Status In Force
Filing Date 2012-01-13
Publication Date 2012-07-19
Owner SCIPHARM SÀRL (Luxembourg)
Inventor
  • Freissmuth, Michael
  • Zebedin-Brandl, Eva-Maria
  • Bergmayr, Christian
  • Hussain, Filza

Abstract

The present invention provides a novel method for enhancing engraftment of haematopoetic stem cells by an ex-vivo pretreatment comprising the steps of obtaining a sample containing haematopoetic stem cells and admixing a prostacyclin analogue to obtain a mixture, incubating said mixture for a period of time sufficient to stimulate G alphas-signalling in said cells and optionally and isolating said stimulated cells. Further, a composition comprising a prostacyclin analogue for use in the treatment of individuals undergoing haematopoetic stem cell transplantation is provided.

IPC Classes  ?

  • A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
  • A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
  • C12N 5/078 - Cells from blood or from the immune system

29.

COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS

      
Application Number EP2010061428
Publication Number 2011/015630
Status In Force
Filing Date 2010-08-05
Publication Date 2011-02-10
Owner SciPharm SàRL (Luxembourg)
Inventor
  • Freissmuth, Michael
  • Koenig, Xaver
  • Gloeckel, Christina

Abstract

The present invention provides compositions comprising a prostacyclin or prostacyclin analogue, or a pharmaceutically acceptable salt thereof for use in preventing or treating cystic fibrosis. The invention also provides the use of a kit comprising a prostacyclin or prostacyclin analogue for treating or preventing a condition associated with cystic fibrosis in a subject.

IPC Classes  ?

  • A61K 31/557 - Eicosanoids, e.g. leukotrienes
  • A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
  • A61P 11/00 - Drugs for disorders of the respiratory system